Q&A with Chris­tine Baed­er, new chair of the gener­ic in­dus­try’s AAM

Gener­ic drugs are more of­ten than not the un­sung he­roes in health­care, gen­er­at­ing bil­lions in sav­ings every year and in­creas­ing ac­cess to vi­tal new med­i­cines as the brand-name ver­sions come off patent.

End­points News con­nect­ed with the new chair of the gener­ic in­dus­try’s As­so­ci­a­tion for Ac­ces­si­ble Med­i­cines, Chris­tine Baed­er, who is al­so Te­va’s COO, via video con­fer­ence on Fri­day.

Baed­er ex­plains be­low not on­ly what’s com­ing for AAM and its mem­ber gener­ic drug com­pa­nies, but al­so her thoughts on the In­fla­tion Re­duc­tion Act and the new five-year FDA user fee deal. Be­low is a light­ly edit­ed and con­densed ver­sion of the in­ter­view.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN